| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Family | 12 | 2021 | 2909 | 2.29 | Why? |
| Intensive Care Units | 68 | 2021 | 29594 | 2.22 | Why? |
| Professional-Family Relations | 5 | 2021 | 424 | 2.16 | Why? |
| Immunocompromised Host | 13 | 2020 | 5150 | 2.07 | Why? |
| Critical Illness | 41 | 2021 | 17281 | 2.04 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 7 | 2021 | 284 | 1.96 | Why? |
| Critical Care | 27 | 2021 | 14081 | 1.92 | Why? |
| Bereavement | 4 | 2021 | 296 | 1.73 | Why? |
| Hematologic Neoplasms | 13 | 2020 | 2105 | 1.59 | Why? |
| Editorial Policies | 3 | 2020 | 408 | 1.47 | Why? |
| Oxygen Inhalation Therapy | 6 | 2019 | 3629 | 1.44 | Why? |
| Respiratory Insufficiency | 13 | 2021 | 7301 | 1.40 | Why? |
| Peer Review, Research | 2 | 2020 | 407 | 1.15 | Why? |
| Invasive Pulmonary Aspergillosis | 4 | 2021 | 634 | 1.02 | Why? |
| Tissue and Organ Procurement | 3 | 2018 | 1277 | 0.98 | Why? |
| Brain Death | 3 | 2018 | 146 | 0.91 | Why? |
| Noninvasive Ventilation | 8 | 2019 | 2329 | 0.88 | Why? |
| Hospital-Patient Relations | 1 | 2020 | 3 | 0.87 | Why? |
| Correspondence as Topic | 2 | 2017 | 50 | 0.85 | Why? |
| Pain Measurement | 4 | 2018 | 533 | 0.84 | Why? |
| Proteoglycans | 2 | 2018 | 130 | 0.81 | Why? |
| Stress Disorders, Traumatic | 1 | 2020 | 78 | 0.81 | Why? |
| Shiga Toxin | 1 | 2018 | 7 | 0.77 | Why? |
| Manuscripts as Topic | 1 | 2018 | 17 | 0.76 | Why? |
| Candidiasis | 3 | 2017 | 334 | 0.76 | Why? |
| Hemolytic-Uremic Syndrome | 1 | 2018 | 22 | 0.75 | Why? |
| Pain, Procedural | 1 | 2018 | 51 | 0.73 | Why? |
| High-Frequency Ventilation | 1 | 2018 | 57 | 0.73 | Why? |
| France | 22 | 2021 | 12074 | 0.72 | Why? |
| Neutropenia | 3 | 2018 | 388 | 0.71 | Why? |
| Pneumonia, Bacterial | 3 | 2021 | 843 | 0.70 | Why? |
| Grief | 3 | 2018 | 320 | 0.68 | Why? |
| Organ Transplantation | 4 | 2020 | 2616 | 0.67 | Why? |
| Periodicals as Topic | 3 | 2020 | 1492 | 0.64 | Why? |
| Long Term Adverse Effects | 1 | 2017 | 119 | 0.64 | Why? |
| Invasive Fungal Infections | 3 | 2019 | 274 | 0.64 | Why? |
| Pneumocystis carinii | 1 | 2018 | 205 | 0.64 | Why? |
| Conflict of Interest | 1 | 2018 | 175 | 0.61 | Why? |
| Amphotericin B | 1 | 2017 | 256 | 0.60 | Why? |
| Comprehension | 1 | 2018 | 259 | 0.59 | Why? |
| Antifungal Agents | 5 | 2020 | 1828 | 0.59 | Why? |
| Sepsis | 6 | 2019 | 3517 | 0.57 | Why? |
| Thrombotic Microangiopathies | 1 | 2018 | 335 | 0.55 | Why? |
| Neoplasms | 13 | 2020 | 17251 | 0.55 | Why? |
| Research Support as Topic | 1 | 2018 | 327 | 0.54 | Why? |
| Pneumonia, Pneumocystis | 1 | 2018 | 322 | 0.54 | Why? |
| beta-Glucans | 1 | 2016 | 176 | 0.53 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.52 | Why? |
| Life Support Care | 2 | 2017 | 161 | 0.51 | Why? |
| Patient Admission | 6 | 2020 | 5250 | 0.50 | Why? |
| Visitors to Patients | 1 | 2020 | 671 | 0.50 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.48 | Why? |
| Organ Dysfunction Scores | 7 | 2020 | 1475 | 0.48 | Why? |
| Intubation, Intratracheal | 5 | 2020 | 3962 | 0.48 | Why? |
| Terminal Care | 3 | 2019 | 928 | 0.47 | Why? |
| Physician's Role | 1 | 2021 | 853 | 0.47 | Why? |
| Steroids | 2 | 2017 | 904 | 0.46 | Why? |
| Physicians | 3 | 2021 | 4214 | 0.46 | Why? |
| Lymphopenia | 2 | 2021 | 2669 | 0.45 | Why? |
| Humans | 122 | 2021 | 930598 | 0.45 | Why? |
| Emotions | 3 | 2018 | 2418 | 0.45 | Why? |
| Heart Diseases | 2 | 2018 | 3503 | 0.43 | Why? |
| Prospective Studies | 24 | 2020 | 43301 | 0.43 | Why? |
| Attitude to Death | 4 | 2018 | 307 | 0.42 | Why? |
| Psychometrics | 2 | 2019 | 1269 | 0.42 | Why? |
| Communication | 2 | 2018 | 5206 | 0.42 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.42 | Why? |
| Hematology | 1 | 2017 | 649 | 0.42 | Why? |
| Nose | 1 | 2017 | 1093 | 0.42 | Why? |
| Attitude of Health Personnel | 3 | 2018 | 4741 | 0.41 | Why? |
| Middle Aged | 62 | 2021 | 270681 | 0.40 | Why? |
| Practice Patterns, Physicians' | 2 | 2020 | 4927 | 0.40 | Why? |
| Depression | 5 | 2021 | 14116 | 0.38 | Why? |
| Male | 65 | 2021 | 367725 | 0.38 | Why? |
| Pain | 1 | 2017 | 1084 | 0.38 | Why? |
| Acute Disease | 6 | 2018 | 6029 | 0.38 | Why? |
| Spouses | 2 | 2021 | 131 | 0.37 | Why? |
| Palliative Care | 3 | 2018 | 2665 | 0.37 | Why? |
| Female | 66 | 2021 | 380317 | 0.37 | Why? |
| Publishing | 1 | 2018 | 990 | 0.36 | Why? |
| Cross Infection | 4 | 2019 | 8675 | 0.36 | Why? |
| Delirium | 2 | 2017 | 1061 | 0.36 | Why? |
| Aged | 47 | 2021 | 215776 | 0.35 | Why? |
| Anxiety | 5 | 2021 | 17311 | 0.35 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.34 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.33 | Why? |
| Lung Diseases, Fungal | 2 | 2016 | 167 | 0.33 | Why? |
| Clinical Decision-Making | 2 | 2020 | 3755 | 0.33 | Why? |
| Respiration, Artificial | 13 | 2020 | 22116 | 0.31 | Why? |
| Adult | 41 | 2021 | 244371 | 0.31 | Why? |
| Antihypertensive Agents | 1 | 2018 | 1962 | 0.30 | Why? |
| Pulmonary Aspergillosis | 2 | 2021 | 408 | 0.29 | Why? |
| Hospital Mortality | 16 | 2020 | 22087 | 0.29 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.29 | Why? |
| Coronavirus Infections | 15 | 2020 | 253789 | 0.29 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.29 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.28 | Why? |
| Organizational Culture | 2 | 2018 | 395 | 0.28 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.28 | Why? |
| Antineoplastic Agents | 2 | 2017 | 3550 | 0.27 | Why? |
| Risk Factors | 20 | 2021 | 71621 | 0.27 | Why? |
| Time Factors | 13 | 2020 | 31397 | 0.27 | Why? |
| Hypoxia | 3 | 2018 | 3626 | 0.27 | Why? |
| Paris | 4 | 2021 | 1287 | 0.26 | Why? |
| Candida | 6 | 2017 | 425 | 0.26 | Why? |
| Qualitative Research | 3 | 2021 | 4337 | 0.26 | Why? |
| Health Personnel | 4 | 2021 | 29646 | 0.26 | Why? |
| International Cooperation | 1 | 2017 | 3436 | 0.25 | Why? |
| Stress, Psychological | 4 | 2020 | 10231 | 0.25 | Why? |
| Multicenter Studies as Topic | 3 | 2020 | 2437 | 0.25 | Why? |
| Airway Extubation | 2 | 2018 | 403 | 0.24 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.24 | Why? |
| Ipilimumab | 2 | 2019 | 102 | 0.23 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.23 | Why? |
| Bacterial Infections | 2 | 2014 | 2229 | 0.23 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.23 | Why? |
| Pneumonia, Ventilator-Associated | 3 | 2018 | 861 | 0.22 | Why? |
| Proportional Hazards Models | 5 | 2020 | 6543 | 0.22 | Why? |
| Glycation End Products, Advanced | 1 | 2021 | 72 | 0.22 | Why? |
| Medical Oncology | 1 | 2017 | 3826 | 0.21 | Why? |
| Herpesviridae | 1 | 2021 | 100 | 0.21 | Why? |
| Receptor for Advanced Glycation End Products | 1 | 2021 | 100 | 0.21 | Why? |
| Dreams | 1 | 2021 | 90 | 0.21 | Why? |
| Granulocyte Colony-Stimulating Factor | 2 | 2018 | 264 | 0.20 | Why? |
| Standard of Care | 2 | 2017 | 1297 | 0.20 | Why? |
| Age Factors | 7 | 2020 | 21039 | 0.20 | Why? |
| Aspergillus | 2 | 2020 | 347 | 0.20 | Why? |
| Catastrophic Illness | 1 | 2019 | 41 | 0.20 | Why? |
| Hypophysitis | 1 | 2019 | 11 | 0.20 | Why? |
| Complement C5 | 1 | 2020 | 139 | 0.20 | Why? |
| Shiga-Toxigenic Escherichia coli | 1 | 2018 | 7 | 0.19 | Why? |
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 12 | 0.19 | Why? |
| Survival Analysis | 5 | 2021 | 7592 | 0.19 | Why? |
| Adult Children | 1 | 2018 | 23 | 0.19 | Why? |
| Transplantation Immunology | 1 | 2018 | 99 | 0.18 | Why? |
| Tumor Lysis Syndrome | 2 | 2018 | 5 | 0.18 | Why? |
| Length of Stay | 7 | 2019 | 11042 | 0.18 | Why? |
| Anemia, Hemolytic, Autoimmune | 2 | 2018 | 199 | 0.18 | Why? |
| Hypotension | 2 | 2019 | 392 | 0.18 | Why? |
| Preliminary Data | 1 | 2020 | 457 | 0.18 | Why? |
| Capillary Permeability | 1 | 2020 | 277 | 0.18 | Why? |
| Medical Staff, Hospital | 3 | 2018 | 1258 | 0.18 | Why? |
| Superior Vena Cava Syndrome | 1 | 2017 | 26 | 0.18 | Why? |
| Common Variable Immunodeficiency | 1 | 2020 | 195 | 0.18 | Why? |
| Retrospective Studies | 20 | 2021 | 105322 | 0.18 | Why? |
| Enterocolitis, Neutropenic | 1 | 2017 | 2 | 0.18 | Why? |
| Complement Inactivating Agents | 1 | 2020 | 254 | 0.18 | Why? |
| Vena Cava, Superior | 1 | 2017 | 30 | 0.18 | Why? |
| Atypical Hemolytic Uremic Syndrome | 1 | 2018 | 62 | 0.17 | Why? |
| Equivalence Trials as Topic | 1 | 2018 | 242 | 0.17 | Why? |
| Belgium | 4 | 2018 | 2064 | 0.17 | Why? |
| Prevalence | 7 | 2021 | 25773 | 0.17 | Why? |
| Acute Kidney Injury | 4 | 2020 | 5762 | 0.17 | Why? |
| Erythrocyte Transfusion | 2 | 2018 | 386 | 0.17 | Why? |
| Pandemics | 16 | 2021 | 389249 | 0.16 | Why? |
| Self-Assessment | 1 | 2018 | 165 | 0.16 | Why? |
| Neuroprotection | 1 | 2016 | 62 | 0.16 | Why? |
| Deep Sedation | 1 | 2017 | 121 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Unnecessary Procedures | 1 | 2018 | 175 | 0.16 | Why? |
| Delphi Technique | 1 | 2021 | 1257 | 0.16 | Why? |
| Cannula | 2 | 2021 | 750 | 0.16 | Why? |
| Severity of Illness Index | 7 | 2020 | 48226 | 0.15 | Why? |
| Thrombosis | 2 | 2019 | 7504 | 0.15 | Why? |
| Consensus | 3 | 2021 | 6345 | 0.15 | Why? |
| Learning Curve | 1 | 2017 | 157 | 0.15 | Why? |
| Respiration | 2 | 2018 | 729 | 0.15 | Why? |
| Immune Sera | 1 | 2020 | 884 | 0.15 | Why? |
| Echinocandins | 1 | 2017 | 139 | 0.15 | Why? |
| Capillary Leak Syndrome | 1 | 2017 | 119 | 0.15 | Why? |
| Survivors | 2 | 2018 | 2619 | 0.15 | Why? |
| Patient Care Bundles | 1 | 2017 | 137 | 0.15 | Why? |
| Candidiasis, Invasive | 1 | 2017 | 107 | 0.15 | Why? |
| Family Health | 1 | 2020 | 731 | 0.14 | Why? |
| Industry | 1 | 2018 | 347 | 0.14 | Why? |
| Laryngoscopes | 1 | 2017 | 121 | 0.14 | Why? |
| Treatment Outcome | 12 | 2020 | 51732 | 0.14 | Why? |
| Biomarkers | 7 | 2021 | 23361 | 0.14 | Why? |
| Carbapenems | 1 | 2018 | 343 | 0.14 | Why? |
| Prognosis | 11 | 2020 | 32490 | 0.14 | Why? |
| Causality | 1 | 2019 | 857 | 0.14 | Why? |
| Quality of Life | 5 | 2019 | 9820 | 0.14 | Why? |
| Hypothermia, Induced | 1 | 2016 | 176 | 0.14 | Why? |
| Immune Tolerance | 1 | 2019 | 608 | 0.14 | Why? |
| Antibodies, Antiphospholipid | 1 | 2019 | 519 | 0.14 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.14 | Why? |
| Immunotherapy | 2 | 2019 | 2421 | 0.14 | Why? |
| Self Concept | 1 | 2019 | 490 | 0.14 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.13 | Why? |
| Diagnostic Errors | 2 | 2019 | 865 | 0.13 | Why? |
| Urate Oxidase | 1 | 2013 | 11 | 0.13 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.13 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.13 | Why? |
| Hyperphosphatemia | 1 | 2013 | 20 | 0.13 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2020 | 10649 | 0.13 | Why? |
| Lung Neoplasms | 2 | 2017 | 3228 | 0.13 | Why? |
| Comorbidity | 8 | 2020 | 34796 | 0.13 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 2426 | 0.13 | Why? |
| Expert Testimony | 1 | 2017 | 658 | 0.13 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.13 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.13 | Why? |
| Plasmapheresis | 1 | 2017 | 437 | 0.13 | Why? |
| Knowledge | 1 | 2017 | 452 | 0.13 | Why? |
| Cross-Sectional Studies | 6 | 2021 | 53120 | 0.13 | Why? |
| Syndrome | 1 | 2018 | 1310 | 0.13 | Why? |
| Research Report | 1 | 2017 | 376 | 0.13 | Why? |
| Professional-Patient Relations | 1 | 2018 | 426 | 0.13 | Why? |
| Surveys and Questionnaires | 6 | 2020 | 43792 | 0.12 | Why? |
| Antiphospholipid Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Acute Lung Injury | 1 | 2021 | 904 | 0.12 | Why? |
| Immunocompetence | 1 | 2014 | 280 | 0.12 | Why? |
| Physical Examination | 1 | 2018 | 755 | 0.12 | Why? |
| Status Epilepticus | 1 | 2016 | 303 | 0.12 | Why? |
| Candidemia | 1 | 2017 | 353 | 0.12 | Why? |
| Ventilator Weaning | 1 | 2017 | 536 | 0.12 | Why? |
| Cancer Survivors | 1 | 2019 | 588 | 0.12 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.12 | Why? |
| Enterobacteriaceae Infections | 1 | 2018 | 529 | 0.12 | Why? |
| Pain Management | 2 | 2017 | 854 | 0.12 | Why? |
| Laryngoscopy | 1 | 2017 | 413 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.11 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.11 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.11 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.11 | Why? |
| Psychiatric Status Rating Scales | 1 | 2018 | 1340 | 0.11 | Why? |
| Phenotype | 2 | 2020 | 4037 | 0.11 | Why? |
| Anticonvulsants | 1 | 2016 | 634 | 0.11 | Why? |
| Combined Modality Therapy | 2 | 2017 | 3395 | 0.11 | Why? |
| Self Report | 3 | 2019 | 3802 | 0.11 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.11 | Why? |
| Bronchoscopy | 1 | 2019 | 991 | 0.11 | Why? |
| Stress Disorders, Post-Traumatic | 2 | 2017 | 2963 | 0.11 | Why? |
| Radiography | 1 | 2018 | 1576 | 0.11 | Why? |
| Health Care Surveys | 1 | 2020 | 2942 | 0.10 | Why? |
| Patient Positioning | 1 | 2021 | 1505 | 0.10 | Why? |
| Logistic Models | 4 | 2019 | 9089 | 0.10 | Why? |
| Workload | 1 | 2021 | 1887 | 0.10 | Why? |
| Empathy | 1 | 2017 | 658 | 0.10 | Why? |
| Research Design | 2 | 2019 | 5830 | 0.10 | Why? |
| Plasma Exchange | 1 | 2017 | 763 | 0.10 | Why? |
| Adaptation, Psychological | 2 | 2018 | 4996 | 0.10 | Why? |
| Biomedical Research | 3 | 2020 | 5270 | 0.10 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.10 | Why? |
| Prone Position | 1 | 2021 | 1861 | 0.10 | Why? |
| Perception | 2 | 2017 | 2827 | 0.10 | Why? |
| Cohort Studies | 5 | 2018 | 36005 | 0.09 | Why? |
| Interviews as Topic | 1 | 2018 | 1952 | 0.09 | Why? |
| B-Lymphocytes | 2 | 2020 | 4418 | 0.09 | Why? |
| Epithelial Cells | 1 | 2021 | 3508 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.09 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.09 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.09 | Why? |
| Coombs Test | 2 | 2018 | 66 | 0.09 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 645 | 0.09 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2017 | 5002 | 0.09 | Why? |
| Workplace | 1 | 2021 | 2075 | 0.09 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| Heart Arrest | 1 | 2018 | 1239 | 0.08 | Why? |
| Decision Making | 2 | 2018 | 3132 | 0.08 | Why? |
| Forecasting | 2 | 2018 | 4492 | 0.08 | Why? |
| Occupational Stress | 1 | 2021 | 2044 | 0.08 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.08 | Why? |
| Sensitivity and Specificity | 2 | 2018 | 22971 | 0.08 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Pneumonia | 3 | 2021 | 5652 | 0.08 | Why? |
| Odds Ratio | 4 | 2018 | 5861 | 0.08 | Why? |
| Disability Evaluation | 1 | 2009 | 671 | 0.08 | Why? |
| ADAMTS13 Protein | 2 | 2021 | 363 | 0.07 | Why? |
| Oxygen | 1 | 2019 | 3715 | 0.07 | Why? |
| Blood Gas Analysis | 2 | 2021 | 893 | 0.07 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Fever | 2 | 2019 | 7795 | 0.07 | Why? |
| Burnout, Professional | 1 | 2021 | 2489 | 0.07 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.07 | Why? |
| APACHE | 2 | 2017 | 682 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.07 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.07 | Why? |
| Attitude to Health | 1 | 2017 | 2002 | 0.07 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.07 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.06 | Why? |
| Nursing Staff, Hospital | 1 | 2017 | 1554 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.06 | Why? |
| Social Support | 1 | 2017 | 3183 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.06 | Why? |
| Multivariate Analysis | 3 | 2018 | 5440 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2018 | 2662 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Incidence | 3 | 2018 | 25622 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2017 | 2739 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3832 | 0.06 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.06 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.06 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.06 | Why? |
| Pulmonary Embolism | 2 | 2017 | 4775 | 0.06 | Why? |
| Propensity Score | 2 | 2021 | 2690 | 0.05 | Why? |
| Models, Statistical | 1 | 2019 | 5312 | 0.05 | Why? |
| Disease-Free Survival | 2 | 2018 | 1654 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.05 | Why? |
| Brain | 1 | 2018 | 5133 | 0.05 | Why? |
| Treatment Failure | 2 | 2017 | 2106 | 0.05 | Why? |
| Fluid Therapy | 2 | 2017 | 628 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Travel | 1 | 2019 | 7220 | 0.05 | Why? |
| Galactose | 1 | 2020 | 201 | 0.05 | Why? |
| Venous Thromboembolism | 1 | 2017 | 4273 | 0.05 | Why? |
| Mannans | 1 | 2020 | 218 | 0.05 | Why? |
| Hypercalcemia | 1 | 2018 | 40 | 0.05 | Why? |
| Hospitalization | 4 | 2018 | 54280 | 0.05 | Why? |
| Sleep Medicine Specialty | 1 | 2019 | 76 | 0.05 | Why? |
| Urinalysis | 1 | 2020 | 218 | 0.05 | Why? |
| Hematuria | 1 | 2020 | 284 | 0.05 | Why? |
| Hematocrit | 1 | 2017 | 107 | 0.04 | Why? |
| Equipment and Supplies, Hospital | 1 | 2020 | 272 | 0.04 | Why? |
| Glasgow Outcome Scale | 1 | 2016 | 56 | 0.04 | Why? |
| Centrifugation | 1 | 2017 | 42 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Antibodies, Fungal | 1 | 2017 | 49 | 0.04 | Why? |
| Multiple Organ Failure | 2 | 2018 | 1724 | 0.04 | Why? |
| Simplified Acute Physiology Score | 1 | 2017 | 102 | 0.04 | Why? |
| Early Ambulation | 1 | 2017 | 102 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1999 | 260 | 0.04 | Why? |
| Pulmonary Atelectasis | 1 | 2017 | 80 | 0.04 | Why? |
| Renal Replacement Therapy | 2 | 2018 | 1530 | 0.04 | Why? |
| Equipment Failure | 1 | 2018 | 197 | 0.04 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.04 | Why? |
| Berlin | 1 | 2016 | 283 | 0.04 | Why? |
| Missouri | 1 | 2017 | 274 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.04 | Why? |
| Alcohol Oxidoreductases | 1 | 1974 | 14 | 0.04 | Why? |
| Ethics, Medical | 2 | 2018 | 533 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Blood Component Transfusion | 1 | 2020 | 740 | 0.04 | Why? |
| Hospitals, University | 2 | 2018 | 4173 | 0.04 | Why? |
| von Willebrand Factor | 1 | 2021 | 668 | 0.04 | Why? |
| Azoles | 1 | 2017 | 185 | 0.04 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.04 | Why? |
| Airway Obstruction | 1 | 2017 | 182 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.04 | Why? |
| Allografts | 1 | 2018 | 761 | 0.03 | Why? |
| Sample Size | 1 | 2017 | 518 | 0.03 | Why? |
| Clinical Protocols | 2 | 2017 | 2734 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Bicarbonates | 1 | 2013 | 33 | 0.03 | Why? |
| Vomiting | 1 | 2019 | 722 | 0.03 | Why? |
| Creatinine | 1 | 2020 | 1443 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2018 | 714 | 0.03 | Why? |
| Allopurinol | 1 | 2013 | 59 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2020 | 1289 | 0.03 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2016 | 403 | 0.03 | Why? |
| Surge Capacity | 1 | 2021 | 894 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Streptococcus pneumoniae | 1 | 2018 | 827 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.03 | Why? |
| Europe | 3 | 2018 | 12702 | 0.03 | Why? |
| Hemodynamics | 1 | 2021 | 1562 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Pulmonary Medicine | 1 | 2019 | 706 | 0.03 | Why? |
| United States | 1 | 2019 | 46150 | 0.03 | Why? |
| Mycoses | 1 | 2018 | 589 | 0.03 | Why? |
| Tumor Burden | 1 | 2013 | 369 | 0.03 | Why? |
| Leukemia | 1 | 2016 | 598 | 0.03 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2018 | 1755 | 0.03 | Why? |
| Pleural Effusion | 1 | 2017 | 680 | 0.03 | Why? |
| Body Temperature | 1 | 2016 | 875 | 0.03 | Why? |
| Workflow | 1 | 2021 | 2373 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Filtration | 1 | 2017 | 820 | 0.03 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.03 | Why? |
| Alkanes | 1 | 1970 | 4 | 0.03 | Why? |
| Medicine | 1 | 2017 | 485 | 0.03 | Why? |
| Rituximab | 1 | 2018 | 1096 | 0.03 | Why? |
| Disease Progression | 1 | 2009 | 13580 | 0.03 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.03 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 800 | 0.03 | Why? |
| Triage | 2 | 2020 | 7151 | 0.03 | Why? |
| Monitoring, Physiologic | 1 | 2021 | 1956 | 0.02 | Why? |
| Lung | 1 | 2018 | 31049 | 0.02 | Why? |
| Sex Factors | 2 | 2017 | 11014 | 0.02 | Why? |
| Electroencephalography | 1 | 2016 | 1242 | 0.02 | Why? |
| Remission Induction | 1 | 2013 | 950 | 0.02 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
| Airway Management | 1 | 2018 | 1298 | 0.02 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.02 | Why? |
| Disaster Planning | 1 | 2021 | 1680 | 0.02 | Why? |
| Fatigue | 1 | 2019 | 2479 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.02 | Why? |
| Mitochondria | 1 | 1974 | 857 | 0.02 | Why? |
| Multiple Myeloma | 1 | 2016 | 1064 | 0.02 | Why? |
| Teaching | 1 | 2016 | 1208 | 0.02 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.02 | Why? |
| Hypersensitivity | 1 | 2017 | 1137 | 0.02 | Why? |
| Needs Assessment | 1 | 2016 | 2352 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Personal Protective Equipment | 2 | 2021 | 15978 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2019 | 2844 | 0.02 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Personnel, Hospital | 1 | 2017 | 2273 | 0.02 | Why? |
| Quality Improvement | 1 | 2016 | 2435 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2018 | 88759 | 0.02 | Why? |
| Emergencies | 1 | 2017 | 4095 | 0.01 | Why? |
| Euthanasia, Passive | 1 | 2000 | 7 | 0.01 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Databases, Factual | 1 | 2016 | 6248 | 0.01 | Why? |
| HIV Seropositivity | 1 | 2003 | 320 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2013 | 7268 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Models, Theoretical | 1 | 2018 | 6659 | 0.01 | Why? |
| Infant, Newborn | 1 | 2000 | 23105 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Intensive Care, Neonatal | 1 | 2000 | 284 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Cytochrome Reductases | 1 | 1974 | 1 | 0.01 | Why? |
| Antimycin A | 1 | 1974 | 5 | 0.01 | Why? |
| Cytochrome c Group | 1 | 1974 | 6 | 0.01 | Why? |
| Membranes | 1 | 1974 | 10 | 0.01 | Why? |
| Centrifugation, Density Gradient | 1 | 1974 | 34 | 0.01 | Why? |
| Cell Fractionation | 1 | 1974 | 44 | 0.01 | Why? |
| Internship and Residency | 1 | 2016 | 4987 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2019 | 14232 | 0.01 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.01 | Why? |
| Genetics, Microbial | 1 | 1970 | 9 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| Soil Microbiology | 1 | 1970 | 63 | 0.01 | Why? |
| Manometry | 1 | 1970 | 91 | 0.01 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.01 | Why? |
| Culture Media | 1 | 1970 | 366 | 0.01 | Why? |
| Glucose | 1 | 1970 | 573 | 0.00 | Why? |
| Oxygen Consumption | 1 | 1970 | 711 | 0.00 | Why? |
| Genetic Variation | 1 | 1970 | 3919 | 0.00 | Why? |